Renin-angiotensin system inhibition and In-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: Findings from CCC-ACS project and a nationwide electronic health record-based cohort in China.
Zhi LiHaonan SunYongchen HaoHangkuan LiuZhengyang JinLinjie LiChong ZhangMin MaTianming TengXiongwen ChenYujun ShenYing YuJing LiuArthur Mark RichardsHuay Cheem TanDong ZhaoXin ZhouQing Yangnull nullPublished in: European heart journal. Quality of care & clinical outcomes (2023)
Based on two nationwide cohorts in China in contemporary practice, we demonstrated that ACEI/ARB therapy initiated within 24 hours of admission is associated with a reduction in in-hospital mortality in ACS patients with advanced renal dysfunction. Clinical Trial Registration: CCC-ACS project was registered at URL: https://www.clinicaltrials.gov. (Unique identifier: NCT02306616).
Keyphrases
- acute coronary syndrome
- electronic health record
- quality improvement
- percutaneous coronary intervention
- antiplatelet therapy
- clinical trial
- oxidative stress
- emergency department
- healthcare
- primary care
- cross sectional
- randomized controlled trial
- study protocol
- open label
- adverse drug
- cell therapy
- coronary artery disease
- bone marrow